Furthermore, the significant reduction in ALT and FLI suggests that oral semaglutide improves liver lipotoxicity due to NAFLD, as previously reported for injectable GLP1-RAs (43) and, recently, for oral semaglutide as well (44). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.